Trials / Completed
CompletedNCT04049903
Study to Investigate the Safety, Blood Levels and Activity of MP0310 in Patients With Advanced Solid Tumors
A First-In-Human, Single-Arm, Multi-Center, Open-Label, Repeated-Dose, Dose-Escalation Study of MP0310 in Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Molecular Partners AG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and tolerability of MP0310, a DARPin® therapeutic candidate for tumor targeted activation of T cells, in patients with advanced solid tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MP0310 | MP0310 will be examined for safety, tolerability, PK, and PD activity in subjects with advanced solid tumors |
Timeline
- Start date
- 2019-09-02
- Primary completion
- 2022-06-27
- Completion
- 2022-12-21
- First posted
- 2019-08-08
- Last updated
- 2022-12-22
Locations
3 sites across 1 country: France
Source: ClinicalTrials.gov record NCT04049903. Inclusion in this directory is not an endorsement.